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Abstract: 
Human CCRL1 belongs to the family of silent chemokine receptors. This transmembrane protein plays a role in blunting function 
of chemokines through binding to them. This will attenuate immune responses. Interaction between CCRL1 and CCL21 determines 
this immune extinction. Thus inhibiting the action of this atypical chemokine seems to stimulate immune responses especially in 
the case of suppressed and immune deficient conditions. In this study we predicted 3D structure of CCRL1 using comparative 
modeling and Hiddebn Markov Model algorithm. Final predicted model optimized by Modeller v9.8 and minimized regarding 
energy level using UCSF chimera candidate version1.5.3. ClasPro webserver was used to find interacting residues between CCRL1 
and CCL21. Interacting residues were used as target for chemical inhibitors by simulated docking study. For finding potential 
inhibitors, library of KEGG compounds screened and 97 obtained chemicals docked against interacting residues between CCRL1-
CCL21 and MolDock was used as docking scoring function. Results indicated that Hexadecanal is a potential inhibitor of CCRL1- 
CCL21 interaction. Inhibition of this interaction will increase intercellular level of CCl21 and interaction between CCL21 and CCR7 
causes immune potentiaiton. 
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Background: 
Chemokines are small proteins fundamentally involved in cell 
migration, angiogenesis, proliferation and apoptosis [1]. 
Chemokines play multifaceted roles in numerous physiological 
and pathological states. Chemokines interact with major seven 
trans-membrane (7TM) receptors of immune system [2]. 
Interaction between CCL19 and CCL21 ligands and CCR7as 
their cognate functional receptor, play a fundamental role in 
lymph node metastasis in many solid tumors [3]. Human 
CCRL1 (Accession number 29169303) contains 350 amino acids 
and is expressed in various tissues as heart, thymus, liver, 
kidney, spleen, lymph node, placenta, brain, trachea, small 
intestine, colon, lung, astrocyte, T cell and dendritic cells [4]. 
CCRL1 belongs to the family of silent chemokine receptors like 
Duffy antigen receptor of chemokines (DARC). These receptors 
lack signaling elements which observed in traditional 
chemokines. This matter enabled them to have a broader 
spectrum of ligands. These chemokines activate no signaling 
cascade. Naturally, these proteins dose not induce a string 
calcium response. These receptors compete in binding to BIOINFORMATION  open access 
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ligands and internalize and degrade ligands. It leads to 
chemokine depletion and inhibition of cell migration. 
Chemokine transcytosis which results in ligand transfer across 
certain barriers is also proposed [5]. It binds and clears the 
constitutively expressed chemokines considered as homeostatic 
chemokines compromising CC chemokine ligands CCL19 
(ELC), CCL21 (SLC, 6Kine), CCL25 (TECK) and CXCL13 (BCA-
1, BLC). These haemostatic chemokines are involved in 
CCR7/CCL19 (CCL21), CCR9/CCL25 and CXCR5/CXCL13 
axes which participate in the process of migration of T cells. 
Migration of T cells to the secondary lymphoid organs affords 
maturity to naive T cells and this is also associated with antigen 
presentation to these lymphatic organs which consequently 
arise defensive immune responses. An atypical chemokine 
receptor as CCRL1 disrupts this chemokine-chemokine receptor 
axis and consequently reduces defensive immune responses. 
Down-regulation of CCL19 and CCL21 in vitro and in vivo with 
consequently has been demonstrated using CCRL1. In the other 
word, CCRL1 is capable to blunt the actions of CCL19 and 
CCL21 through disrupting the interaction of these chemokines 
with their functional receptor. Indeed, xenographs transfected 
with this atypical chemokine binder indicated significant 
reduction in CCL25 and CXCL13 concentration with a high 
clearance capability for post-translational chemokine targeting. 
In this regard, natural decoy chemokine receptors were 
observed to potentially block attraction of these chemokines.  
 
Chemokine sequestration using atypical receptors as decoy 
receptors [6] has a negative regulation on the development of 
proper immune responses. This chemokine scavenging might 
be a new therapeutic avenue for stimulation and potentiaiton of 
immune responses and treatment of immune-deficient diseases 
states. Therefore, the aim of this study is finding potential 
agonists for this protein.  
 
Methodology: 
CCRL1 sequence obtained from NCBI database with Accession 
number 29169303 and CCL21 crystallographic structure 
retrieved from Protein Data Bank with PDB number 2L4N.   
 
Prediction of 3-D structure 
In order to predict the 3D structure of CCRL1, three web servers 
were used. In the first approach we used automated mode of 
swissmodel.  [7] This server predicts query 3D model using 
comparative modeling method based. This server used 
template of intracellular loop of the alpha 2A adrenergic 
receptor (1ho9) Chain: A for prediction of the query. As an 
alternative approach phyre2 server [8] was used. Any 20 
identical amino acids between query and templates is a hit for 
this server. After finding similar structures, this server predicts 
query model based on identical folds. Phyre2 output model was 
predicted based on template of Family a G protein-coupled 
receptor-like (d1u19a) from family of Rhodopsin-like.The 
model constructed by this method showed high coverage (97%) 
and template alignment confidence (100%) values. Also a 
Hidden Markov Model based server used for modeling of 
CCRL1. SAM-T08 server [9] first makes HMM cluster from 
query and then aligns this cluster against a HMM database 
which is constructed from PDB structures and finally generates 
model based on HMM alignment. Therefore numbers of 
misaligned residues decrease by using this algorithm. 
 
Model evaluation 
Q-mean score [10] was used for evaluation of predicted models. 
Q-mean is a parameter between 0-1. Scores reach near 1 are 
similar to crystallographic structure. But tranmembrane 
proteins even in crystallographic structures reach low score. 
The model Predicted by swissmodel reached score of 0.05 and 
score of phyre2 was 0.271 and SAM-T08 predicted model 
reached 0.440. Predicted models by Phyre2 and swissmodel did 
not cover all of query residues while in the SAM-T08 output all 
of 350 residues were modelled. Because of reaching highest 
score in Q-mean and complete query coverage, the SAM-T08 
output was chosen for further study (Figure 1).  
 
 
Figure1: SAM-T08 predicted model of CCRL1 
 
Model optimization 
Modeller v9.8 [11] was used for optimization of SAM-T08 
predicted model. Optimization was performed in 10 steps. Also 
100 steps of structure minimization were performed using 
UCSF chimera candidate version1.5.3. During this step the date 
interval was 10 and step size was set on 0.02.  
 
Virtual screening 
Using FindSite server, the KEGG compounds library was 
screened for potentially binding ligands 97 poten ligands were 
obtained. These ligands were used for further simulated 
docking study in order to find best inhibitor structure.  
 
Molecular docking study 
molegro virtual docker (MVD) 2011.4.3.0 used for computer 
simulated docking study. Before initiation of the docking 
operation, protein and ligand structures were prepared using 
MVD. For this purpose charges assigned to the model of protein 
and ligands structures and flexible torsions in ligands were 
detected by this software. This approach also identified 
probable missing explicit hydrogens and assigned possible 
missing bonds. Side chain minimization of the derived CCRL1 
and CCL21 models was performed during which only torsion 
angles in the side chains of model were modified and other 
properties (bond lengths & backbone atom positions) were kept 
unchanged. 
 
Discussion: 
Prediction of interacting residues between CCRL1 and CCL21 
Binding CCL21 to CCRL1 causes activation of CCRL1 inducing 
intracellular signal transduction and decreasingm the number BIOINFORMATION  open access 
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of free CCL21 molecules. As the result formation of the CCL21-
CCR7 complex which is an immune activator is decreased. This 
cause immune extinction in masked immune diseases. Thus, 
inhibition of the interaction between CCRL1-CCL21 causes 
formation of a CCL21-CCR7 complex and activation of the 
immune response. For preventing this interaction, interactive 
residues must be defined. To do this we used ClasPro [12], a 
rigid body based protein-protein docking webserver. In the 
output data, interaction of CCL21 with N-terminal of CCRL1 
with least energy level (-979.9 in scale of Weighted Score) was 
selected and by using ligand scout software we detected that 
residues number 138, 142, 143, 144 and 226 are interacting 
residues of CCRL1.  
 
 
Figure2: (A) 2D and (B) 3D structure of Hexadecanal 
 
Molecular docking study 
MolDock score [13] with a grid resolution of 0.30 Ȃ used as 
scoring function for docking. Internal electrostatic interaction 
and hydrogen bond between ligand and protein were 
permitted. MolDock SE was used as the docking algorithm and 
ten runs for ligands were carried out. After docking, energy 
minimization and optimization of hydrogen bonds performed. 
The energy threshold was 100.00 and similar poses were 
ignored. Docking radius was defined to cover amino acids 
positions 138, 142, 143, 144 and 226 which were predicted as 
interactive residues with CCL21. Using these docking radius 
results finding a chemical compound which can bind exactly in 
the interaction place and act as a potential inhibitor of 
interaction between CCRL1-CCL21. Docking results evaluated 
based on MolDock and Re-ranking score. Re-rank score is 
estimation for interaction. For the defined docking radius in N-
terminal of CCRL1, the best pose derived from MolDock score 
was -142.991with Reranking score equal to -70.069. Table 1 (see 
supplementary material) describes energy level of five top pose 
of best inhibitor structure. Also 2D and 3D structure of the 
ligand is depicted in (Figure 2). 
 
 
Figure 3: interaction between CCRL1 and Hexadecanal. This 
interaction is in the exact place of interacting residues of CCRL1 
with CCL21 
 
Identification of inhibitor structure 
PubChem database was used for identification of the inhibitor 
structure and Hexadecanal found as our query. Interaction 
between CCRL1 and Hexadecanal is depicted in (Figure 3). 
Hexadecanal (drug bank: DB03381) with chemical formula 
C16H32Ois and aldehyde which drives from degradation of 
sphinganine. As a therapeutic application of hexadecanal, it has 
been reported that injection of this chemical can prevent growth 
of goiter in rat. [14] After increasing the intracellular level of 
hexadecanal, fatty acyl-CoA reductase oxidizes this chemical to 
hexadecanoyl-CoA. This product can follow fatty acids 
oxidation pathway in cell and detoxifies in this pathway. 
Inhibitory effect of hexadecanal on CCRL1-CCL21 interaction is 
due to its flexible carbon chain and its aldehyde functional 
group. It is probable that any similar and synthetic structure 
can have similar inhibitory effect.  
 
Conclusion: 
Based on obtained binding energy level between hexadecanal 
and CCRL1, it is mostly probable that binding this potential 
inhibitor to CCRL1 occupies interaction site of CCRL1 and 
CCL21.  Occupation of this place prevents formation of CCRL1 
and CCL21 complex. Thus, increased free CCL21 molecules 
result in its interaction with CCR7. After binding CCR7 to 
CCL21, this complex can potentiate immune responses through 
enhanced conveying of immune antigens to secondary 
lymphoid organs. Then, we suggest that any synthetic and 
drug-like compound similar to hexadecanal can be used as a 
potential inhibitor of CCRL1-CCL21 complex for further 
experimental analysis in order to stimulate immune responses. 
This might be valuable in the stimulating of attenuated immune 
system.   
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Supplementary material: 
 
MolDock scoring function, Escoreis: 
Escore = Einter+ Eintra 
Einteris defined as ligand-protein interaction energy: 
 
EPLPterm: a piecewise linear potential 
The second term describes the electrostatic interactions between charged atoms 
Eintrais the internal energy of the ligand: 
 
 
Table 1: binding energy level of top five poses of Hexadecanal to CCRL1 
Ligand name  MolDock Score  Rerank Score  HBond 
Hexadecanal  -142.991   -70.069           8.45892 
Hexadecanal   -129.6428  -7.03469     -2.5 
Hexadecanal    -128.2786    -71.6903   0 
Hexadecanal -127.4818  -73.7083  0 
Hexadecanal -127.3446  -70.2874  0 
For more information see supplementary data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 